Biomarin Announces First Person Treated Commercially With Ro

Biomarin Announces First Person Treated Commercially With Roctavian® (Valoctocogene Roxaparvovec-Rvox) For Severe Hemophilia A In Europe

Biomarin Announces First Person Treated Commercially With Roctavian® (Valoctocogene Roxaparvovec-Rvox) For Severe Hemophilia A In Europe

menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Germany , Italy , France , Berlin , United States , Jeff Ajer , Vivantes Klinikum , Robert Klamroth , Nasdaq , Prnewswire Biomarin Pharmaceutical Inc , Biomarin Pharmaceutical Inc , First Person Treated , Reimbursement Discussions , Commercially Available , Marin Pharmaceutical , Activities Accelerating , Eligibility Testing , About Hemophilia , Safety Information , Biomarin Pharmaceutical , Common Adverse Reactions , Reproductive Potential , Prescribing Information , Important Safety ,